Prostate Cancer Screening in African-American Men

Video
Conference|American Association for Cancer Research Annual Meeting (AACR)

In this video, Dr. Judd Moul discusses disparities in prostate cancer screening among African-American men, and the need for more research in this area.

In this video, Dr. Judd Moul discusses disparities in prostate cancer screening among African-American men, and the need for more research in this area.

Related Videos
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Related Content
Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.

BCRFS Seen With Apalutamide Combo in Entire High-Risk Prostate Cancer Group

May 5th 2024
Article

Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

May 30th 2022
Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

Functional consequences appeared to be lower with HIFU compared with radical prostatectomy in a prospective trial.

HIFU Yields Noninferior Outcomes Vs Prostatectomy in Local Prostate Cancer

May 3rd 2024
Article

Functional consequences appeared to be lower with HIFU compared with radical prostatectomy in a prospective trial.

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

April 26th 2022
Podcast

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

April 15th 2024
Article

Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.

Novel CAR T-Cell Therapy Yields Response in R/R Non-Hodgkin Lymphoma

Novel CAR T-Cell Therapy Yields Response in R/R Non-Hodgkin Lymphoma

April 14th 2024
Article

HR001 was found to have an efficacious response for patients with relapsed/refractory non-Hodgkin lymphoma.